Azenta licenses Elegen gene synthesis platform and acquires SynPlexity
On October 28, 2026, Azenta entered a license agreement and a supply agreement with Elegen Corp. for cell-free DNA synthesis technology, and acquired all outstanding stock of SynPlexity Inc., a DNA assembly technology company. The company expects aggregate capital deployment under the Elegen agreements of approximately $32 million to $71 million, depending on future equipment purchases and whether it converts the license to a perpetual one. The filing gives no revenue, profit, or guidance figures, so its direct effect on results is not quantified.
Key points
- Elegen license is exclusive and royalty-free for specified gene synthesis products, with an initial term of five years.
- Azenta has an option, exercisable 12 to 18 months after execution, to convert the license to a perpetual exclusive one for $25 million plus any unpaid license fees.
- Expected aggregate capital deployment under the Elegen agreements is approximately $32 million to $71 million.
- SynPlexity acquisition closed concurrently with signing on October 28, 2026; the filing does not state the purchase price.
The filing
Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.